Avalo Therapeutics, Inc. (AVTX)
| Market Cap | 343.55M |
| Revenue (ttm) | 59,000 |
| Net Income (ttm) | -78.26M |
| Shares Out | 26.71M |
| EPS (ttm) | -5.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 831,787 |
| Open | 14.24 |
| Previous Close | 14.42 |
| Day's Range | 12.63 - 15.09 |
| 52-Week Range | 3.39 - 20.72 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 40.57 (+215.47%) |
| Earnings Date | May 8, 2026 |
About AVTX
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1β-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1β, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania. [Read more]
Financial Performance
In 2025, Avalo Therapeutics's revenue was $59,000, a decrease of -86.62% compared to the previous year's $441,000. Losses were -$78.26 million, 122.8% more than in 2024.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for AVTX stock is "Strong Buy." The 12-month stock price target is $40.57, which is an increase of 215.47% from the latest price.
News
Avalo Therapeutics Purchases Optional Milestone Buyout
WAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune...
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune...
Avalo Therapeutics Transcript: Leerink Global Healthcare Conference 2026
AVTX-009, a selective anti-IL-1β antibody, completed a large phase II-B trial in HS with data expected in Q2 2025. The drug aims to surpass competitors by offering higher affinity, better dosing, and strong efficacy, with future expansion planned in validated inflammatory indications.
Avalo Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
AVTX-009, a high-affinity IL-1 beta antibody, is positioned for best-in-disease efficacy in HS, leveraging superior potency and trial rigor. Phase II data, expected soon, will inform rapid advancement to Phase III and broader market opportunities, with a differentiated safety profile and potential ancillary benefits.
Avalo Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
HS is a large, underdiagnosed market with rapid growth. AVTX-009, a high-affinity anti-IL-1β antibody, is positioned for differentiation through its mechanism, dosing, and safety. Phase II LOTUS trial data is expected next quarter, with phase III planning to follow.
Avalo Therapeutics to Participate in Upcoming Investor Conferences
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated i...
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
WAYNE, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated i...
Avalo Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
AVTX-009's phase IIb LOTUS trial in moderate to severe HS is fully enrolled, with data expected in Q2 2026. The study targets IL-1 beta, aiming for a 20% or greater placebo-adjusted response, and positions the drug as a high-affinity, long-acting competitor in a crowded field.
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case
Avalo Therapeutics Inc.'s (NASDAQ: AVTX) completed enrollment of the Phase 2 LOTUS trial of AVTX-009, the company's lead drug candidate.
Avalo Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Top-line data from the phase II LOTUS trial in HS is expected in Q2, with robust enrollment and rigorous site qualification supporting strong statistical power. The program aims for phase III advancement, leveraging a differentiated IL-1 beta mechanism and planning for broader indications.
Avalo Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit
AVTX-009, a high-affinity anti-IL-1 Beta antibody, is advancing in phase 2B trials for HS, leveraging strong scientific rationale and robust clinical design. Rapid enrollment and high investigator interest reflect market enthusiasm, with expectations for strong efficacy, a favorable safety profile, and significant commercial opportunity.
Avalo Therapeutics Transcript: Stifel 2025 Healthcare Conference
AVTX-009, a high-affinity anti-IL-1β antibody, is in phase 2b for HS, targeting a key inflammatory pathway. The trial is fully enrolled, with data expected mid-next year, and aims to set a new efficacy benchmark. Cash runway extends through 2028, with future expansion into other IL-1β-driven diseases.
Avalo Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
AVTX-009, a high-affinity anti-IL-1 beta antibody, is in a fully enrolled phase II-B trial for HS, with data expected mid-next year. The asset is differentiated by its mechanism, higher affinity, and dosing, and the company is exploring broader indications with a strong balance sheet.
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026 Appointed Kevin Lind to Board of Directors Expanded leadership tea...
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated i...
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated i...
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated ...
Avalo Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum
AVTX-009, a high-affinity anti-IL-1β antibody, is advancing through a well-enrolled phase IIb trial for hidradenitis suppurativa, with topline data expected mid-2025. The program is supported by strong scientific rationale, a favorable safety profile, and a robust cash position.
Avalo Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
AVTX-009, a high-affinity anti-IL-1 beta antibody, is advancing in phase 2B trials for hidradenitis suppurativa, targeting a large unmet need with top-line data expected mid-2026. Strong financials support expansion into additional IL-1 beta-driven diseases.
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated i...
Avalo Therapeutics Transcript: HCW Annual Inflammation & Immunology Virtual Conference 2025
AVTX-009, a potent anti-IL-1β antibody, is in phase II-B for hidradenitis suppurativa, targeting a significant unmet need with a differentiated mechanism and robust trial design. The company is well-funded, aims for phase III in 2027, and sees broad market and pipeline potential.
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appo...
Avalo Therapeutics Transcript: Jefferies Global Healthcare Conference 2025
IL-1β is validated as a key target in HS, with AVTX-009 offering superior affinity, potency, and dosing advantages over competitors. The ongoing phase II LOTUS trial is designed for robust efficacy assessment, with data expected in mid-2026. Significant market need and future pipeline expansion are anticipated.
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business ...
Avalo Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025
A high-affinity IL-1 beta antibody is in phase two for Hidradenitis Suppurativa, aiming for best-in-class efficacy with convenient dosing and global enrollment. Market potential is significant, with expansion opportunities in multiple immune-mediated diseases and a strong financial runway into 2027.